Quarterly ResultMay 14, 2026, 04:13 PM
Jasper Therapeutics Q1 Net Loss $1.2M; Advances Briquilimab Program
AI Summary
Jasper Therapeutics, Inc. reported a net loss of $1.2 million for the first quarter ended March 31, 2026, with cash and cash equivalents totaling $14.1 million. The company provided a corporate update, including the appointment of Jeet Mahal as Chief Executive Officer and the refiling of an updated Phase 2b protocol with the FDA for briquilimab in chronic spontaneous urticaria (CSU). Jasper also highlighted positive updated data from its briquilimab studies in CSU from January 2026, showing high response rates, and plans to commence the Phase 2b study in the second half of 2026, pending additional funding.
Key Highlights
- Jasper Therapeutics reported a net loss of $1.2 million for Q1 2026.
- Cash and cash equivalents totaled $14.1 million as of March 31, 2026.
- Research and development expense was $5.8 million for the quarter.
- General and administrative expense was $5.1 million for the quarter.
- Net loss per share attributable to common stockholders was $0.04.
- Jeet Mahal was appointed as Chief Executive Officer.
- Refiled an updated Phase 2b protocol with the FDA for briquilimab in CSU.
- Reported positive updated data from briquilimab studies in CSU in January 2026.